| 1 |
33667670 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. | 2021 Jun |
1 |
| 2 |
34140289 | "Significant Activity" for ADC in Ovarian Cancer. | 2021 Aug |
1 |
| 3 |
30413525 | Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. | 2019 Mar 15 |
1 |
| 4 |
31369274 | Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer. | 2019 Sep 3 |
1 |
| 5 |
29098867 | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. | 2018 Jan |
1 |
| 6 |
29424243 | FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. | 2018 Jul |
2 |
| 7 |
29440294 | In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. | 2018 May |
1 |
| 8 |
27889646 | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. | 2016 Dec |
1 |